Description

This grant opportunity funds research projects that utilize real-world evidence to evaluate the clinical impact of early versus delayed initiation of ritlecitinib in treating alopecia areata (AA). The focus is on assessing outcomes such as hair regrowth, response durability, relapse rates, disease trajectory, and identifying patient and disease characteristics that predict benefit from early intervention. Comparative studies with conventional treatment pathways and exploration of the potential for disease modification with early ritlecitinib use are encouraged. The aim is to generate data that inform optimal treatment timing and improve patient outcomes in diverse populations affected by AA.